BRAF and colorectal cancer: In the 2012 Cancer Genome Atlas Network study [61], KRAS mutations presented in 43.0% of non-hypermutated colorectal cancers and 30.0% of hypermutated colorectal cancers while, BRAF mutations presented in 3.0% of non-hypermutated colorectal cancers and 47.0% of hypermutated colorectal cancers.